Jacqueline M Becker, NP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 278 Vt Route 149, Mettowee Valley Family Health Center, West Pawlet, VT 05775 Phone: 802-645-0580 Fax: 802-645-0587 |
Ms. Rebecca Kay Heflin, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 278 Vt Route 149, West Pawlet, VT 05775 Phone: 802-645-0580 Fax: 802-645-0587 |
Ayla Lewis Carr, FNP-C Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 278 Vt Route 149, West Pawlet, VT 05775 Phone: 802-645-0580 Fax: 802-645-0587 |
News Archive
Synthetech, Inc. today announced financial results for the first quarter of fiscal 2011, which ended June 30, 2010. Revenue for the quarter was $2.0 million, a 56% decrease compared to revenue of $4.7 million in the first quarter of fiscal 2010. The operating loss for the current quarter was $727,000, compared to operating income of $1.0 million for the same period last year. The net loss for the current quarter was $763,000, or $0.05 per basic share, compared to last year's first quarter net income of $969,000, or $0.07 per basic share.
Lawmakers set to move a budget through the California legislature are pushing back against a plan by Gov. Jerry Brown to cut health care benefits - notably for in-home care, kids, the elderly and the disabled.
When stem cell transplant first became part of standard treatment for certain cancers and blood diseases twenty years ago, individuals older than 60 were rarely considered for the procedure.
On average, American colleges and universities with nursing programs offer about one hour of instruction in handling catastrophic situations such as nuclear events, pandemics, or water contamination crises, according to two recent studies co-authored by a nursing professor at the University of Tennessee, Knoxville.
Today's major announcement at the American Society of Clinical Oncology annual meeting that the drug exemestane significantly reduces the risk of breast cancer in high-risk, postmenopausal women is the result of an international, randomized double-blind phase III clinical trial in which University at Buffalo researchers and hundreds of Western New York women played a critical role.
› Verified 6 days ago